Table 2.

Clinical Applications of Flumazenil and Ro15-4513

Tracer	PET Nuclide	Experimental Condition	Reference
Flumazenil	[18F]	Unilateral Ischemic Stroke	25
Flumazenil	[18F]	Temporal Lobe Epilepsy	24
Flumazenil	[18F]	Children with Cerebral Palsy	33
Flumazenil	[18F]	Ultra-High Risk for Psychosis	26
Flumazenil	[18F]	Schizophrenics taking Aripiprazole	27
Flumazenil	[18F]	Aversive-Aversive Stimulus	34
Flumazenil	[18F]	Internal vs. External Awareness	28
Flumazenil	[18F]	Healthy – Cortical Thickness	29
Flumazenil	[11C]	Acute Triazolophthalazine α51A Dose	20
Flumazenil	[11C]	Cerebellar Ataxia	19
Flumazenil	[11C]	Epileptic Newborns	21
Flumazenil	[11C]	Tiagibine GAT-1 Blockade	22
Flumazenil	[11C]	Primary Distonia	23
Ro15-4513	[11C]	Induced Acute GABA increase	30
Ro15-4513	[11C]	History of Cigarette Smoking	31
Ro15-4513	[11C]	Acute Zolpidem Dose	32
Ro15-4513	[11C]	Alcohol-Dependent Men	35
Ro15-4513	[11C]	Autism Spectrum Disorder	36